Using imaging biomarkers to accelerate drug development and clinical trials (Q36039936)

11 August 2017

1 reference

title

Using imaging biomarkers to accelerate drug development and clinical trials (English)

1 reference

11 August 2017

0 references

Homer H Pien

1

1 reference

11 August 2017

Alan J Fischman

series ordinal

2

1 reference

11 August 2017

James H Thrall

series ordinal

3

1 reference

11 August 2017

A Gregory Sorensen

series ordinal

4

1 reference

11 August 2017

1 February 2005

1 reference

11 August 2017

1 reference

11 August 2017

10

1 reference

11 August 2017

4

1 reference

11 August 2017

259-266

1 reference

The price of innovation: new estimates of drug development costs

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Clinical biomarkers in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

The value of improving the productivity of the drug development process: faster times and better decisions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Magnetic resonance imaging in drug discovery: lessons from disease areas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Molecular imaging of cancer with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Are surrogate markers adequate to assess cardiovascular disease drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Scaling down imaging: molecular mapping of cancer in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Shedding light onto live molecular targets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Can small animal imaging accelerate drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Molecular Imaging: Looking at Problems, Seeing Solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Serial magnetic resonance imaging in experimental primate stroke: validation of MRI for pre-clinical cerebroprotective trials

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Attrition and Translation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Structural, Functional, and Molecular MR Imaging of the Microvasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Functional computed tomography in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Surrogate markers in antiangiogenesis clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Assessment of the Patient with Hyperacute Stroke: Imaging and Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

1 reference

7 January 2021

Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

In vivo diffusion–perfusion magnetic resonance imaging of acute cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Fast magnetic resonance diffusion-weighted imaging of acute human stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Usefulness of magnetic resonance-derived quantitative measurements of cerebral blood flow and volume in prediction of infarct growth in hyperacute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

The role of positron emission tomography in pharmacokinetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903334-3

7 January 2021

10.1016/S1359-6446(04)03334-3

Identifiers

DOI

1 reference

11 August 2017

1 reference